Alternatives to Next Vial

⛔ FDA warning letter #728279 (June 2026), which names tryeden.com. The most oversight-forward compounded program here — visible clinician involvement and lab framing — at $196/mo semaglutide or $296/mo tirzepatide, flat and nationwide.

• $3/mo cheaper than Next Vial
• serves all 50 states, where Next Vial lists Not published
• scores 89/100 against Next Vial's 53

The widest menu on our roster — injections, sublingual lozenges, daily drops, four brand-name pens and the approved oral GLP-1 — with three compounding pharmacies named, a flat price at any dose, and cancellation terms among the most restrictive we have read.

• serves all 50 states, where Next Vial lists Not published
• offers FDA-approved brand pens, not just compounded
• has an oral option if you would rather not inject

Now confirmed to publish real GLP-1 prices — compounded semaglutide from $199, tirzepatide from $349, plus brand options — right on its products page, no consult required, contrary to what an earlier check found.

• serves all 50 states, where Next Vial lists Not published
• offers FDA-approved brand pens, not just compounded
• has an oral option if you would rather not inject

The price-first pick: some of the lowest flat, all-inclusive compounded pricing we track, nationwide — strong if the monthly number is your deciding factor and you read the annual-prepay fine print.

• $24/mo cheaper than Next Vial
• serves all 50 states, where Next Vial lists Not published
• scores 80/100 against Next Vial's 53

A rare compounded-plus-brand shop with five real price points disclosed up front — $179/mo compounded semaglutide up to $1,086/mo brand Zepbound — though the oral tablet's exact molecule split isn't fully clear, and there's no postpartum or PCOS-specific content.

• $20/mo cheaper than Next Vial
• serves all 50 states, where Next Vial lists Not published
• offers FDA-approved brand pens, not just compounded

A clean, all-50-states compounded option with named pharmacies, no membership and the consult included — reasonable and transparent on price, though it's a newer platform with thin public detail beyond the $199 headline.

• serves all 50 states, where Next Vial lists Not published
• has an oral option if you would rather not inject
• scores 78/100 against Next Vial's 53

Four named pharmacies, a named prescribing partner and brand-name Wegovy, Zepbound and Ozempic alongside the compounded line — that is a fuller disclosure than most of this roster manages. Compounded GLP-1 injections start at $179 a month and daily dissolvable tablets at $249, and the price attaches to the form rather than the molecule: the product page never says whether you are getting semaglutide or tirzepatide, and the terms confirm both are in scope. Two things deserve a mother's attention before she enrolls. The brand products are priced as a membership plus an undisclosed medication cost, and that membership is quoted at two different figures on one page, $99 beside Zepbound and Wegovy and $171 beside Ozempic. And the terms state that if a provider decides a different molecule suits you better, staying enrolled is itself your consent to the switch and the charges continue. It also discloses, unusually plainly, that people shown in its advertising may be actors or artificial intelligence rather than clinicians.

• $20/mo cheaper than Next Vial
• serves all 50 states, where Next Vial lists Not published
• offers FDA-approved brand pens, not just compounded

Both molecules have confirmed, tiered pricing, which appears only inside the signup flow — the public site carries no price at all — with a real gotcha: the 3-month plan costs more per month than month-to-month.

• serves all 50 states, where Next Vial lists Not published
• offers FDA-approved brand pens, not just compounded
• scores 71/100 against Next Vial's 53

An uncommon needle-free option — both semaglutide and tirzepatide sold as an oral tablet as well as an injection — with all-50-states coverage clearly disclosed, though its $179/mo semaglutide rate is explicitly a promo and its headline weight-loss stats are self-reported, not clinical.

• $20/mo cheaper than Next Vial
• serves all 50 states, where Next Vial lists Not published
• offers FDA-approved brand pens, not just compounded